HIV Infections Clinical Trial
Official title:
Enhancing Message Design in Tailored, Computerized HIV/STI Interventions
The purpose of the current study is to test a computerized HIV/STD prevention program with heterosexual African Americans. The hypothesis is that those exposed to the program will increase their correct and consistent use of condoms compared to those not exposed to the program.
The proposed study will involve the development and pilot testing of an interactive
computerized tailored intervention program for HIV/STI prevention among at-risk
heterosexually active African-American STI clinic patients, aged 18-29. The
Attitude-Social-Influence Efficacy (ASE) model will serve as a conceptual foundation for the
intervention and tailored feedback, which will assess and give feedback to participants
separately for main/steady and other/casual partners. Individual modules will be developed
for key theoretical concepts and subsequently tied together into an integrated system. The
tailored feedback will additionally be enhanced by crafting intervention messages to be high
in message sensation value and by developing interactive intervention activities for
skill-building, which will be guided by both Social Cognitive Theory and skills training
principles. The computerized intervention will be developed and guided using data collected
from the target audience to ensure an empirically-based approach to tailoring. The
intervention will also be developed with input from the target audience in order to maximize
the appropriateness and persuasiveness of the feedback and the program, including
interactive components. The final year of the project will entail a pilot test of the
intervention in order to gather preliminary data on the acceptability and efficacy of such
an intervention for increasing safer sexual behaviors among at-risk heterosexually active
African-Americans.
The specific aims of the study are: 1) to develop tailored feedback on HIV/STI prevention
based on the ASE model, including condom attitudes, social influences, self-efficacy
including communication / negotiation skills, partner and behavioral risk, correct condom
use, and condom stages of change; 2) to enhance the delivery of the tailored messages using
sensation-seeking targeting (SENTAR) and skill-building using interactive activities guided
by Social Cognitive Theory (SCT) and skills training principles; 3) to tie the individual
theoretical modules together and develop a computerized intervention program for HIV/STI
prevention, which provides tailored risk reduction messages to participants based upon an
assessment of participant characteristics; 4) to develop empirically sound cutpoints,
specific to the target audience, to guide the message tailoring; and 5) in a wait-list
control group design, to pilot test the intervention for acceptability and efficacy in
increasing condom use with main and casual partners among at-risk heterosexually active
African-Americans, relative to a "usual care" comparison condition.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |